SILVER SPRING, MD. — In nearly unanimous votes, a Food and Drug Administration advisory panel agreed that data on Gardasil supported the efficacy and safety of the vaccine for use in preventing genital warts caused by human papillomavirus types 6 and 11 in boys and men aged 9-26 years.
PREVIEW